FDA Follow-On Biologics Background Document To Be Released By Year-End
Executive Summary
FDA is developing a background document as part of its ongoing action on "follow-on" biologics, Acting Commissioner for Operations Janet Woodcock, MD, said
You may also be interested in...
FDA Personnel Moves Signal Continuity Under Commissioner Crawford
Five top-level FDA personnel appointments implemented July 29 suggest general agency policy will likely go unchanged in the near future
FDA Personnel Moves Signal Continuity Under Commissioner Crawford
Five top-level FDA personnel appointments implemented July 29 suggest general agency policy will likely go unchanged in the near future
Generic Biologics Legislation Unlikely, But Issue Not Going Away
The push for legislation creating a follow-on biologics pathway is "cooling off," Senate Aging Committee majority counsel Steve Irizarry told the Stanford Washington Research Group conference in Washington, D.C. May 5